Quick Answer
SANGAMO THERAPEUTICS, INC reported Net Income Loss of -$122.93 million for the year ending 2025.
- SANGAMO THERAPEUTICS, INC showed a decrease of -25.5% in Net Income Loss from 2024 to 2025.
- This data is from SANGAMO THERAPEUTICS, INC's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), SANGAMO THERAPEUTICS, INC's Net Income Loss has declined by 561.4%.
- Historical annual values: Fiscal year 2025: -$122.93 million | Fiscal year 2024: -$97.94 million | Fiscal year 2023: -$257.83 million | Fiscal year 2022: -$192.28 million | Fiscal year 2021: -$178.29 million | Fiscal year 2020: -$121.00 million | Fiscal year 2019: -$95.19 million | Fiscal year 2018: -$68.33 million | Fiscal year 2017: -$54.57 million | Fiscal year 2016: -$71.66 million | Fiscal year 2015: -$40.70 million | Fiscal year 2014: -$26.42 million | Fiscal year 2013: -$26.62 million | Fiscal year 2012: -$22.26 million | Fiscal year 2011: -$35.75 million | Fiscal year 2010: -$24.85 million | Fiscal year 2009: -$18.59 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: